GB0207224D0 - Tenascin-W compositions and uses thereof - Google Patents

Tenascin-W compositions and uses thereof

Info

Publication number
GB0207224D0
GB0207224D0 GBGB0207224.7A GB0207224A GB0207224D0 GB 0207224 D0 GB0207224 D0 GB 0207224D0 GB 0207224 A GB0207224 A GB 0207224A GB 0207224 D0 GB0207224 D0 GB 0207224D0
Authority
GB
United Kingdom
Prior art keywords
tenascin
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0207224.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Novartis Forschungsstiftung
Original Assignee
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institut
Novartis Forschungsstiftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research, Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institut, Novartis Forschungsstiftung filed Critical Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Priority to GBGB0207224.7A priority Critical patent/GB0207224D0/en
Publication of GB0207224D0 publication Critical patent/GB0207224D0/en
Priority to AU2003215673A priority patent/AU2003215673A1/en
Priority to US10/509,009 priority patent/US7683159B2/en
Priority to CA002480050A priority patent/CA2480050A1/en
Priority to EP03744857A priority patent/EP1490400A2/en
Priority to JP2003578416A priority patent/JP4469180B2/ja
Priority to PCT/EP2003/003150 priority patent/WO2003080663A2/en
Priority to US12/688,363 priority patent/US20100173314A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB0207224.7A 2002-03-27 2002-03-27 Tenascin-W compositions and uses thereof Ceased GB0207224D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0207224.7A GB0207224D0 (en) 2002-03-27 2002-03-27 Tenascin-W compositions and uses thereof
AU2003215673A AU2003215673A1 (en) 2002-03-27 2003-03-26 Tenascin-w compositions and uses thereof
US10/509,009 US7683159B2 (en) 2002-03-27 2003-03-26 Tenascin-W compositions and uses thereof
CA002480050A CA2480050A1 (en) 2002-03-27 2003-03-26 Tenascin-w compositions and uses thereof
EP03744857A EP1490400A2 (en) 2002-03-27 2003-03-26 Tenascin-w compositions and uses thereof
JP2003578416A JP4469180B2 (ja) 2002-03-27 2003-03-26 テネイシンｗ組成物およびその使用
PCT/EP2003/003150 WO2003080663A2 (en) 2002-03-27 2003-03-26 Tenascin-w compositions and uses thereof
US12/688,363 US20100173314A1 (en) 2002-03-27 2010-01-15 Diagnostic methods using tenascin-w compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0207224.7A GB0207224D0 (en) 2002-03-27 2002-03-27 Tenascin-W compositions and uses thereof

Publications (1)

Publication Number Publication Date
GB0207224D0 true GB0207224D0 (en) 2002-05-08

Family

ID=9933815

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0207224.7A Ceased GB0207224D0 (en) 2002-03-27 2002-03-27 Tenascin-W compositions and uses thereof

Country Status (7)

Country Link
US (2) US7683159B2 (enExample)
EP (1) EP1490400A2 (enExample)
JP (1) JP4469180B2 (enExample)
AU (1) AU2003215673A1 (enExample)
CA (1) CA2480050A1 (enExample)
GB (1) GB0207224D0 (enExample)
WO (1) WO2003080663A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160507A0 (en) * 2001-08-24 2004-07-25 Advanced Cell Tech Inc Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy
WO2009053354A1 (en) * 2007-10-22 2009-04-30 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Use of tenascin-w as a biomarker for colon cancer
EP2241323A1 (en) * 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
GB201413357D0 (en) * 2014-07-28 2014-09-10 Philogen Spa Antibodies for treatment and diagnosis
CA3068688A1 (en) * 2017-06-30 2019-01-03 National Institutes Of Biomedical Innovation, Health And Nutrition Biomarker for detecting colorectal cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004464A2 (en) 1990-09-05 1992-03-19 The Wistar Institute Monoclonal antibodies against tenascin
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
US6124260A (en) 1998-09-30 2000-09-26 Cedars-Sinai Medical Center Inhibition of smooth muscle cell migration by Tenascin-C peptides
AU2001238585A1 (en) * 2000-02-24 2001-09-03 Human Genome Sciences, Inc. Human polynucleotides, polypeptides, and antibodies
US20030022255A1 (en) 2000-12-22 2003-01-30 Morris David W. Novel compositions and methods for breast cancer
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer

Also Published As

Publication number Publication date
CA2480050A1 (en) 2003-10-02
US7683159B2 (en) 2010-03-23
AU2003215673A1 (en) 2003-10-08
JP4469180B2 (ja) 2010-05-26
WO2003080663A2 (en) 2003-10-02
JP2006504397A (ja) 2006-02-09
US20050202430A1 (en) 2005-09-15
WO2003080663A3 (en) 2004-04-01
US20100173314A1 (en) 2010-07-08
EP1490400A2 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
EP1539941A4 (en) ADZYMES AND THEIR USES
GB0212062D0 (en) Jetable compositions
IL169441A0 (en) Hemostatic compositions and uses therefor
IL165372A0 (en) Immunodenic compositions
GB0411940D0 (en) Methods and compositions
EP1701725A4 (en) PROCESS AND COMPOSITIONS
GB0229742D0 (en) Novel compounds and uses thereof
AU2003256805A8 (en) Compounds compositions and methods
IL166331A0 (en) 5-arylterazole compounds compositions thereof and uses therefor
GB0208609D0 (en) Compositions
SI1551805T1 (sl) Substituirani gama-fenil-delta-laktami in njihova uporaba
EP1539191A4 (en) COMPOSITIONS CONTAINING GLYCO ALKALOIDS AND THEIR VARIOUS USES
GB0221894D0 (en) Compositions
GB0203395D0 (en) Compositions
GB2384705B (en) Cosmetic and related compositions
GB0203396D0 (en) Compositions
AU2003231827A8 (en) Pseudo-tissues and uses thereof
GB0207224D0 (en) Tenascin-W compositions and uses thereof
AU2003268078A8 (en) Levothyroxine compositions and methods
GB0325942D0 (en) Compositions and uses thereof
GB0217366D0 (en) Compositions
AU2003258772A8 (en) Novel neutracetical and pharmaceutical compositions and their uses
GB0211949D0 (en) Novel compounds compositions and processes
AU2003216382A8 (en) Idothyronine compositions
GB0223316D0 (en) Compositions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)